Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …

Rivaroxaban has been found to be noninferior to warfarin for preventing stroke or systemic
embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate …

Objective To conduct a systematic review of economic models of newer anticoagulants for
stroke prevention in atrial fibrillation (SPAF). Patients and Methods We searched Medline …

Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …